These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY Front Immunol; 2021; 12():705378. PubMed ID: 34526987 [TBL] [Abstract][Full Text] [Related]
6. Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma. Sun BY; Zhang D; Gan W; Wu JF; Wang ZT; Sun GQ; Zhou J; Fan J; Yi Y; Hu B; Zhang BH; Qiu SJ J Cancer Res Clin Oncol; 2024 Jul; 150(7):348. PubMed ID: 39002018 [TBL] [Abstract][Full Text] [Related]
7. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma. Saung MT; Zheng L Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624 [TBL] [Abstract][Full Text] [Related]
8. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215 [TBL] [Abstract][Full Text] [Related]
9. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations. Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ Front Immunol; 2022; 13():872295. PubMed ID: 35634282 [TBL] [Abstract][Full Text] [Related]
11. Exercise Training Improves Tumor Control by Increasing CD8 Gomes-Santos IL; Amoozgar Z; Kumar AS; Ho WW; Roh K; Talele NP; Curtis H; Kawaguchi K; Jain RK; Fukumura D Cancer Immunol Res; 2021 Jul; 9(7):765-778. PubMed ID: 33839688 [TBL] [Abstract][Full Text] [Related]
12. Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review. Zhang W; Luo C; Zhang ZY; Zhang BX; Chen XP Front Immunol; 2022; 13():1079342. PubMed ID: 36700218 [TBL] [Abstract][Full Text] [Related]
13. Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. Amaro A; Reggiani F; Fenoglio D; Gangemi R; Tosi A; Parodi A; Banelli B; Rigo V; Mastracci L; Grillo F; Cereghetti A; Tastanova A; Ghosh A; Sallustio F; Emionite L; Daga A; Altosole T; Filaci G; Rosato A; Levesque M; Maio M; Pfeffer U; Croce M; J Exp Clin Cancer Res; 2023 Mar; 42(1):67. PubMed ID: 36934257 [TBL] [Abstract][Full Text] [Related]
14. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. Lu JC; Zeng HY; Sun QM; Meng QN; Huang XY; Zhang PF; Yang X; Peng R; Gao C; Wei CY; Shen YH; Cai JB; Dong RZ; Shi YH; Sun HC; Shi YG; Zhou J; Fan J; Ke AW; Yang LX; Shi GM Theranostics; 2019; 9(16):4678-4687. PubMed ID: 31367249 [No Abstract] [Full Text] [Related]
15. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Wu L; Yun Z; Tagawa T; Rey-McIntyre K; de Perrot M Mol Cancer Ther; 2012 Aug; 11(8):1809-19. PubMed ID: 22584123 [TBL] [Abstract][Full Text] [Related]
16. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840 [TBL] [Abstract][Full Text] [Related]
18. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370 [TBL] [Abstract][Full Text] [Related]
19. Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8 Zhu Y; Wang XY; Zhang Y; Xu D; Dong J; Zhang Z; Yi CH; Jia HL; Yang X Cancer Manag Res; 2018; 10():4113-4123. PubMed ID: 30323667 [TBL] [Abstract][Full Text] [Related]
20. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]